Home
Team
Russell Hirsch
David Schnell
Alex Barkas, In Memoriam
About
What We Do
What We've Achieved
Contact
Portfolio
News

Prospect Venture Partners

Home
Team
Russell Hirsch
David Schnell
Alex Barkas, In Memoriam
About
What We Do
What We've Achieved
Contact
Portfolio
News
David Schnell
November 12, 2018

November 12, 2018 - NGM Bio Announces Preliminary Results from Phase 1b Study of NGM313 in Obese, Insulin Resistant Subjects with Nonalcoholic Fatty Liver Disease (NAFLD)

David Schnell
November 12, 2018

Source:https://www.ngmbio.com/ngm-bio-announces-preliminary-results-from-phase-1b-study-of-ngm313-in-obese-insulin-resistant-subjects-with-nonalcoholic-fatty-liver-disease-nafld/

Newer PostJanuary 3, 2019 - Merck Exercises Option for NGM Bio’s Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes
Older PostNovember 9, 2018 - NGM Bio Announces New Histology Data from Phase 2 Trial of NGM282 in NASH Patients

Contact Prospect
Venture Partners:

Address:
525 University Ave., Suite 1350
Palo Alto, CA 94301

Phone:
(650) 327-8800

Prospect Ventures Funds:
Prospect Venture Partners I
Prospect Venture Partners II
Prospect Venture Partners III

 Connect with Prospect Ventures:
 Prospect Ventures on LinkedIn
 Prospect Ventures on Crunchbase
 Prospect Ventures on Bloomberg
 Prospect Ventures on CB Insights
 Prospect Ventures on Palico
 Prospect Ventures on Index.co
 Prospect Bio Ventures

Back to Top

© 2018 - Prospect Venture Partners.. All Rights Reserved
No content on this site may be republished or reprinted without written permission from Prospect Venture Partners